Jaime E. Moss, Managing Associate Attorney
Jaime E. Moss is a Managing Associate attorney responsible for managing the Hermosa Beach, California office of The Michael Brady Lynch Firm, which specializes in mass tort pharmaceutical litigation on behalf of individuals injured by dangerous and defective drugs and medical devices.
Jaime attended the University of California, Los Angeles where she graduated summa cum laude with a Bachelor of Arts in Sociology and earned Dean’s Honors status. She went on to attend Thomas Jefferson School of Law in San Diego, California, where she obtained her Juris Doctorate. Jaime graduated as a Jefferson Fellow, ranked at the top of her law school class with summa cum laude honors. She was on the Distinguished Honor Roll, was nominated for the Burton Award for Legal Writing, and graduated with a Certificate from the Center for Law and Intellectual Property. Jaime was published in the Thomas Jefferson Law Review twice and served as a staff associate, notes editor and articles editor.
Jaime is a member of the California Bar and is admitted in all federal district courts in California, the Ninth Circuit Court of Appeals, and the U.S. Court of Federal Claims. Jaime is a member of the American Association for Justice.
Prior to joining The Michael Brady Lynch Firm, Jaime gained valuable experience in products liability litigation as an associate in a mass tort litigation firm and subsequently was named as a partner. She managed various pharmaceutical drug and medical device cases from intake to settlement. Jaime has worked with plaintiffs’ steering and executive committees, and has represented plaintiffs injured by a variety of dangerous and defective drugs and medical devices in both state court coordinated litigations and federal multi-district litigations, including Essure, Crestor, GranuFlo, SSRI antidepressants, Zofran, Bair Hugger, breast implants, Medtronic Infuse, NuvaRing, Yaz, Mirena, implantable cardioverter defibrillators, talcum powder, Benicar, Invokana, Pradaxa, and Xarelto.
Jaime enjoys working on emerging pharmaceutical litigations to stand up for consumers’ rights and safety when they have been harmed. She also has a passion for research and writing about issues involving drug safety, mass tort litigation, and FDA reform. Jaime has authored numerous published articles, including: “Patients at Risk: The Need to Amend the Food, Drug, and Cosmetic Act to Ensure the Safety of Imported Prescription Drugs,” Thomas Jefferson Law Review, Vol. 33, Issue 2; “The Problem with Generic Drug Labels,” Los Angeles Daily Journal, November 30, 2011; “The Implications of the Supreme Court’s Decision Regarding Labeling and Liability of Generic Drugs,” Thomas Jefferson Law Review, Vol. 35, Issue 1, Fall 2012; “Use of GranuFlo During Hemodialysis May Subject Patients to Serious Cardiac Risks,” published in the HB Litigation Conferences e-zine; “The Intersection of Law and Technology In Pharmaceutical Litigation,” published in the ABA Tort, Trial & Insurance Practice’s (TIPS) newsletter The Pulse, News From The Medicine & Law Committee. Winter 2015; “Identifying Authorized Generic Drugs”- published in the Good Counsel column of Trial Magazine, October 2016; Peer Reviewer/Editor for an article appearing in AAJ’s Trial Magazine, April 2017.
Jaime is a New York native, who moved to Southern California over a decade ago, and has fully embraced the lifestyle. She enjoys running, biking, hiking, yoga, the beach, photography, and good wine.